2016  0,799
2015  0,662
2014  0,740
2013  0,739
2012  0,637
2011  0,658
2010  0,654
2009  0,570
2008  0,849
2007  0,805
2006  0,330
2005  0,435
2004  0,623
2003  0,567
2002  0,641
2001  0,490
2000  0,477
1999  0,762
1998  0,785
1997  0,507
1996  0,518
1995  0,502
Vol 51(2017) N 6 p. 804-812; DOI 10.1134/S0026893317060024 Full Text

V.V. Argentova1*, T.K. Aliev2, V.V. Zarubaev3, S.A. Klotchenko3, A.A. Shtro3, M.V. Sergeeva3, V.A. Toporova4, D.A. Dolgikh1,4, P.G. Sveshnikov5, V.A. Vasin3, M.P. Kirpichnikov1,4

In vitro Antiviral Activity of Recombinant Antibodies of IgG and IgA Isotypes to Hemagglutinin of the Influenza A Virus

1Department of Bioengineering, Faculty of Biology, Moscow State University, Moscow, 119234 Russia
2Department of Chemical Enzymology, Faculty of Chemistry, Moscow State University, Moscow, 119234 Russia
3Research Institute of Influenza, Ministry of Healthcare of the Russian Federation, St. Petersburg, 197376 Russia
4Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, 117997 Russia
5Russian Research Center for Molecular Diagnostics and Therapy, Moscow, 117149 Russia

Received - 2017-04-28; Accepted - 2017-06-26

Seasonal and highly infectious strains of the influenza A and influenza B viruses cause millions of cases of severe complications in elderly people, children, and patients with immune diseases each year. Immunoglobulin A (IgA), which is an active component of humoral immunity, can prevent the spread of the virus in the upper respiratory tract. The preparation and study of the properties of recombinant virus-specific IgA could be an important approach to finding new means of preventing and treating influenza. Based on CHO DG44 cells, we developed stable monoclonal cell lines that produce monomeric and dimeric antibodies FI6-IgA1 and FI6-IgA2m1 to hemagglutinin (HA) of the influenza A virus. When studying the productivity, growth, and stability of the obtained clones, we found that the dimeric form of antibodies of IgA1 isotype is superior to other forms. The dimeric form of IgA antibodies plays a key role in mucosal immunity. Recognizing the prospects of using dimeric IgA as prophylactic and therapeutic mucosal drugs for viral infections, we studied their virus-neutralizing and antiviral activities on MDCK cell culture and compared them with the antibodies of the IgG1 isotype. This study presents the data on antiviral and virus-neutralizing activities of the FI6-IgA1 dimers to seasonal and highly infectious strains of influenza A virus.

influenza A virus, stable cell lines, IgG1, IgA2, dimeric IgA1, antiviral activity